Last updated: August 1, 2026
Mithracin, also known as plicamycin or mithramycin A, is an older antineoplastic antibiotic with no established active commercial market and no meaningful modern clinical-trial pipeline. The U.S. Food and Drug Administration approved injectable plicamycin for selected testicular tumors and for short-term treatment of hypercalcemia associated with malignancy, but its clinical use declined because of severe hepatic, renal, hematologic and gastrointestinal toxicity. Current activity is concentrated in laboratory research on mithramycin derivatives, transcription-factor biology and oncology mechanisms rather than development of Mithracin as an approved medicine.[1-4]
What is Mithracin and what is its FDA-approved use?
Mithracin is the historical brand name for plicamycin, also called mithramycin A. It is an aureolic-acid antineoplastic antibiotic produced by Streptomyces plicatus. The compound binds preferentially to GC-rich DNA sequences and interferes with transcription. Its pharmacologic effects include inhibition of RNA synthesis and suppression of selected transcriptional programs.[2,5]
The historical U.S. label identified two principal uses:
- Treatment of selected testicular neoplasms.
- Short-term management of hypercalcemia associated with advanced malignancy.
Mithracin was administered intravenously. It was never positioned as a broad, first-line oncology treatment. Its therapeutic window was narrow, and dose-limiting toxicity restricted repeated administration.
What are the principal safety limitations of plicamycin?
The main safety concerns are:
- Hepatotoxicity, including potentially severe liver injury.
- Thrombocytopenia and other marrow toxicity.
- Renal injury.
- Gastrointestinal toxicity.
- Coagulopathy and bleeding risk.
- Electrolyte disturbances.
- Tissue injury if extravasation occurs.
The toxicity profile, availability of safer alternatives and changes in oncology practice materially reduced its clinical relevance. Modern management of malignancy-associated hypercalcemia generally relies on agents such as zoledronic acid, pamidronate, denosumab or, in selected cases, calcitonin and disease-directed therapy.[1,6]
What is the current clinical-trial status of Mithracin?
Mithracin has no established late-stage clinical development program. Public trial registries and the biomedical literature show that contemporary research has focused mainly on preclinical studies and exploratory translational work rather than randomized trials designed to support a new approval.
| Development category |
Current assessment |
| Historical approved drug |
Yes, plicamycin had an FDA-approved use |
| Active broad oncology development program |
No established program |
| Phase 3 program |
None identified |
| Phase 2 registration program |
None identified |
| Modern hypercalcemia development program |
No meaningful active program |
| Biosimilar pathway |
Not applicable |
| Generic substitution pathway |
Limited by product availability and regulatory status |
| Research activity |
Preclinical and mechanistic studies continue |
ClinicalTrials.gov is the principal U.S. registry for interventional studies. Searches for plicamycin, mithramycin and mithramycin A have not established a current commercial trial program comparable to active oncology drugs.[3]
Are mithramycin derivatives in clinical development?
Mithramycin derivatives have attracted research interest because the parent compound affects transcription factors implicated in cancer, including SP1-regulated pathways. Derivative programs have attempted to preserve antitumor activity while reducing toxicity or improving pharmacologic properties.
That research should not be treated as evidence that Mithracin itself has returned to clinical development. A derivative with a distinct chemical structure, sponsor, formulation or clinical-trial identifier would require separate regulatory and patent analysis.
What is the FDA regulatory status of Mithracin?
Mithracin’s regulatory position is best described as historical approval with limited present-day commercial relevance. The original product is not a current standard treatment for either testicular cancer or malignancy-associated hypercalcemia.
The FDA-approved indication does not establish current market availability. A product can retain historical regulatory status while being discontinued, unavailable, or commercially irrelevant. FDA labeling and drug databases should be reviewed separately from commercial wholesaler listings and hospital formulary data.[1,7]
Is Mithracin listed in the Orange Book?
Mithracin does not have a meaningful current Orange Book patent-exclusivity position. Any historical composition, formulation or use patents associated with plicamycin would have expired many years ago. The commercial issue is product availability and regulatory reintroduction, not an active patent barrier.
The FDA Orange Book is designed primarily to identify approved drug products, therapeutic equivalence evaluations and listed patent or exclusivity information. It is not a complete record of every historical patent associated with a compound.[7]
When did Mithracin lose market exclusivity?
Mithracin’s original market exclusivity expired decades ago. The compound was first approved in the United States in the early 1970s, placing any ordinary small-molecule patent term associated with the original product well outside the current exclusivity period.
| Exclusivity category |
Current status |
| New chemical entity exclusivity |
Expired |
| Original composition patents |
Expired |
| Original formulation patents |
Expired |
| Method-of-use patents for historical indications |
Expired or commercially irrelevant |
| Pediatric exclusivity |
None of practical current relevance |
| Orphan-drug exclusivity |
No current exclusivity position identified |
| Active Orange Book patent estate |
No meaningful estate identified |
A party seeking to commercialize plicamycin today would therefore rely on regulatory strategy, manufacturing capability, clinical evidence and supply economics rather than legacy patent protection.
What patents protect Mithracin today?
No active patent estate is known to provide meaningful exclusivity for the original plicamycin molecule. The relevant historical IP categories were likely directed to the compound, pharmaceutical preparations, production methods or therapeutic use. Those rights are now expired based on the age of the product.
Potentially relevant modern IP could exist around:
- New plicamycin analogues.
- Targeted delivery systems.
- Liposomal or nanoparticle formulations.
- Combination regimens.
- Manufacturing improvements.
- Synthetic biology or engineered microbial production.
- New oncology indications.
Those rights would protect specific inventions rather than the historical Mithracin product. A new formulation patent would not automatically prevent use of an unprotected plicamycin formulation, and a derivative patent would not necessarily cover the parent molecule.
Does Mithracin face biosimilar risk?
No. Mithracin is a small-molecule antibiotic, not a biologic. Biosimilar approval rules under the Public Health Service Act do not apply. Any competitive product would proceed through a small-molecule drug pathway, subject to the product’s regulatory classification and available reference-product documentation.
Which companies are challenging Mithracin?
No significant current Paragraph IV litigation or commercial challenge involving Mithracin is established. The product’s competitive problem is different from that of a high-revenue branded drug facing generic entry.
A Paragraph IV challenge requires an abbreviated new drug application referencing an approved drug and asserting that listed patents are invalid, unenforceable or not infringed. Because Mithracin has no meaningful current patent estate or active branded market, it does not present the typical high-value Paragraph IV litigation profile.[7,8]
What litigation affects Mithracin?
No active, material patent litigation is known to define the product’s commercial outlook. Historical disputes, if any, would not materially change the current assessment because the original exclusivity period has ended and the product has little observable market presence.
What is the commercial market for Mithracin?
The current commercial market is negligible relative to active oncology medicines. Mithracin has no established revenue base comparable to modern anticancer drugs, no broad hospital demand and no visible branded launch strategy.
| Market factor |
Assessment |
| Current branded sales |
No meaningful established market |
| Chronic oncology use |
Minimal |
| Hypercalcemia use |
Supplanted by newer agents |
| Hospital demand |
Limited and specialized |
| Pricing power |
Low without new clinical differentiation |
| Generic competition |
Theoretical, but constrained by demand and product availability |
| Manufacturing economics |
Challenging for a low-volume injectable |
| Investor value |
Primarily research or platform-based, not product-revenue based |
Mithracin’s historical indication for hypercalcemia is particularly vulnerable to substitution. Zoledronic acid and denosumab have stronger contemporary clinical adoption, while treatment of the underlying cancer remains central to disease management.[6]
What is the revenue exposure of Mithracin?
There is no material publicly established revenue exposure for a major pharmaceutical company based on Mithracin sales. The product should not be modeled as a current revenue-generating oncology asset unless a sponsor demonstrates:
- Active manufacturing.
- Regulatory authorization to market.
- A defined supply channel.
- Reimbursement coverage.
- Current clinical demand.
- A documented commercial launch.
Without those elements, a revenue model based on historical approval would overstate the asset’s value.
How strong is the Mithracin patent estate?
The patent estate for the original molecule is weak from a present commercial perspective. Its age eliminates conventional composition-of-matter protection, while the absence of a significant current market limits the value of any residual know-how.
| Patent-strength dimension |
Rating |
Commercial implication |
| Composition-of-matter protection |
Low |
Historical rights are expired |
| Formulation protection |
Low |
Legacy formulations offer little exclusivity |
| Method-of-use protection |
Low |
Historical uses are mature |
| Manufacturing know-how |
Moderate potential |
Could matter if production is difficult |
| Derivative IP |
Potentially stronger |
Applies only to new analogues |
| Regulatory exclusivity |
None of current significance |
No current protection against competition |
| Litigation leverage |
Low |
No material patent block is apparent |
Manufacturing know-how may have more practical value than patent rights. Plicamycin is a complex natural-product molecule, and reliable production, purification, stability and sterile injectable manufacturing could be difficult at commercial scale. Those barriers can delay entry, but they do not create the legal exclusivity of an unexpired patent.
What generic launch risks exist for Mithracin?
A generic launch is legally more plausible than commercially attractive. The main barriers are:
- Limited or discontinued reference-product availability.
- Difficulty demonstrating pharmaceutical equivalence.
- Sterile injectable manufacturing requirements.
- Small addressable patient population.
- Hospital procurement uncertainty.
- Toxicity-related demand constraints.
- Availability of safer alternatives.
- Potential need for additional clinical or pharmacology support if the reference product cannot be readily characterized.
A sponsor could pursue a conventional abbreviated pathway if a suitable reference product and regulatory framework remain available. If not, the program could require a more burdensome application strategy, increasing development cost and timing risk.
How does Mithracin compare with current hypercalcemia treatments?
Mithracin is disadvantaged on safety, convenience and clinical familiarity.
| Treatment |
Current role in malignancy-associated hypercalcemia |
Relative position versus Mithracin |
| Zoledronic acid |
Established antiresorptive therapy |
Generally preferred because of clinical familiarity |
| Pamidronate |
Established antiresorptive therapy |
More commonly used than plicamycin |
| Denosumab |
Important option, including refractory cases |
Stronger modern positioning |
| Calcitonin |
Rapid but short-term effect |
Used in selected acute settings |
| Mithracin |
Historical or highly limited role |
Weaker safety and commercial position |
Mithracin could become commercially relevant only through a clearly differentiated use, such as a new formulation, biomarker-selected cancer indication or derivative with materially improved tolerability.
What is the market projection for Mithracin through 2030?
The base-case forecast is a negligible approved-drug market through 2030. The most probable path is continued use in research, limited historical-reference activity and no broad commercial relaunch.
| Scenario |
Probability assessment |
2030 commercial outcome |
| Base case |
Most likely |
No meaningful commercial market |
| Specialty reintroduction |
Low |
Limited hospital or oncology use after regulatory redevelopment |
| Derivative success |
Low |
Value shifts to a new molecule, not legacy Mithracin |
| Research-only continuation |
Likely |
Academic and preclinical demand without product revenue |
| Generic re-entry |
Low |
Small, unstable injectable market |
A relaunch would require a sponsor to overcome three constraints at once: demonstrate a clinically relevant benefit, establish a reliable sterile supply chain and obtain reimbursement in a market dominated by newer therapies. Patent protection would not provide the primary incentive. Regulatory exclusivity for a new indication or formulation could improve the economics, but it would depend on a new development program.
Key Takeaways
- Mithracin is plicamycin, an older injectable antineoplastic antibiotic.
- Its historical FDA uses were selected testicular tumors and short-term malignancy-associated hypercalcemia.
- No meaningful active commercial clinical-trial program is established.
- The original molecule has no commercially relevant patent exclusivity.
- Mithracin is not subject to biosimilar competition because it is a small molecule.
- Modern hypercalcemia treatments have displaced it in routine practice.
- Current revenue exposure is negligible.
- The principal barriers to re-entry are toxicity, clinical demand, manufacturing and regulatory redevelopment.
- Any investable opportunity is more likely to involve a new mithramycin derivative or delivery technology than the legacy product.
FAQs About Mithracin
Is Mithracin still available in the United States?
Mithracin is not a routinely available oncology product in the U.S. market. Historical FDA approval should not be interpreted as evidence of current commercial supply.
Is plicamycin the same drug as mithramycin?
Yes. Plicamycin is the generic name associated with mithramycin, mithramycin A and the historical brand Mithracin.
Can Mithracin be used instead of denosumab?
Mithracin is not a routine substitute for denosumab. Denosumab has a stronger modern role in malignancy-associated hypercalcemia and refractory disease.
Is mithramycin A being studied for cancer?
Mithramycin A continues to appear in preclinical oncology research, especially involving transcriptional regulation and cancer-cell signaling. That research does not establish an active approval-directed clinical program for Mithracin.
Would a new Mithracin formulation receive patent protection?
A genuinely novel formulation, delivery system or manufacturing process could qualify for patent protection if it meets patentability requirements. Such protection would cover the specific invention and would not restore expired exclusivity for the original plicamycin molecule.
References
- U.S. Food and Drug Administration. (n.d.). Plicamycin injection prescribing information.
- National Cancer Institute. (n.d.). Plicamycin. NCI Drug Dictionary.
- ClinicalTrials.gov. (n.d.). Search results for plicamycin, mithramycin and mithramycin A. U.S. National Library of Medicine.
- PubChem. (n.d.). Plicamycin. National Center for Biotechnology Information.
- Remers, W. A. (Ed.). (1990). The chemistry of antitumor antibiotics. Wiley.
- National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Cancer-related hypercalcemia.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Paragraph IV certification and patent listing information.
